151 studies (12 from unattributed sources) on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 139 | 99.77% | View COA → |
| Lilipeptide | 135 | 99.56% | View COA → |
| Shanghai Sigma Audley Ssa | 126 | 99.45% | View COA → |
| Qing Li Peptide | 118 | 99.62% | View COA → |
| Unknown vendor (review) | 117 | 99.79% | View COA → |
| Nexaph | 115 | 99.41% | View COA → |
| Bfflist Amo | 105 | 99.71% | View COA → |
| Peptaris | 105 | 99.29% | View COA → |
Recent certificates: #26981 (99.69%) · #26982 (99.91%) · #27579 (99.87%) · #30753 (99.94%) · #38586 (99.75%) · #42718 (99.9%)
Manufacturers with published third-party certificates of analysis for Retatrutide. Open a vendor to see every batch we've verified.
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
Understanding how kidney function affects LY3437943's pharmacokinetics is crucial for ensuring patient safety and guiding appropriate dosing strategies across diverse populations. This data is essential for developing…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
If successful, this Phase 3b trial could establish Retatrutide as a highly effective and safe treatment option for obesity and overweight, potentially offering superior weight loss outcomes compared to existing therap…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This comprehensive review underscores the transformative potential of incretin polyagonists to redefine obesity treatment paradigms. By offering a non-surgical option with efficacy approaching that of bariatric surger…
This comprehensive review is critical for guiding clinicians and policymakers in India to implement evidence-based and effective obesity management strategies. By synthesizing the latest data and expert consensus from…
The findings underscore the critical role of multi-targeted approaches in effectively treating the complex pathology of MASLD. This comprehensive overview provides a roadmap for future drug development, emphasizing th…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
This hypothetical study strongly suggests that integrating resistance exercise with incretin-based weight loss pharmacotherapy is critical for optimizing body composition, mitigating sarcopenia (age-related muscle los…
This study highlights a critical issue: the lack of diverse representation and transparent reporting in obesity clinical trials significantly limits the generalizability and safety assessment of new medications. If tr…
The development of oral GLP-1 RAs represents a significant leap forward, offering a more convenient and patient-friendly option that can greatly improve adherence to treatment for Type 2 Diabetes. Furthermore, the adv…
This study provides compelling evidence that retatrutide, a novel triple agonist, is highly effective in reducing liver fat and achieving MASLD resolution in a substantial proportion of patients. The remarkable rates …
This review underscores the transformative potential of GIP receptor-based therapies as a powerful new class of drugs for obesity management. The impressive weight loss and metabolic improvements observed suggest thes…
This review significantly advances our understanding of the multifaceted nature of obesity, providing a robust framework for developing more effective and personalized treatments. The detailed exploration of molecular…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This comprehensive comparison provides crucial evidence for clinicians and patients, guiding treatment decisions for obesity and overweight. The identification of most effective agents can lead to more personalized an…
This comprehensive meta-analysis solidifies retatrutide's position as a highly effective treatment for obesity and related metabolic disorders, offering a robust evidence base for its broad therapeutic potential. The …
This review is crucial for clinicians and researchers, underscoring the need for a paradigm shift in Type 2 Diabetes (T2D) management from a purely pharmacological approach to a holistic, integrated model. It emphasiz…
This systematic review provides compelling evidence that incretin therapies, especially GLP-1 receptor agonists, are not merely glucose-lowering agents but also offer significant cardiovascular protection for individu…
Preserving fat-free mass during weight loss is paramount for maintaining metabolic health, physical function, and reducing frailty, especially in older adults. This review underscores the urgent need for anti-obesity …
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This comprehensive systematic review provides robust evidence that GLP-1 receptor agonists are highly effective and generally safe pharmacological interventions for significant weight loss in adults without diabetes. …
This comprehensive meta-analysis provides robust evidence supporting the superior efficacy and acceptable safety profile of retatrutide as a potent treatment for obesity. The substantial weight loss achieved, averagin…
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
This review underscores the transformative potential of GLP-1RAs in addressing the global obesity epidemic and its related health burdens. The significant and sustained weight loss observed with these agents, coupled …
Understanding these sex-specific differences is crucial for advancing personalized medicine approaches in obesity and type 2 diabetes management. This finding suggests that biological sex may be an important factor in…
This review underscores the significant potential of repurposing GLP-1 RAs as a novel therapeutic strategy for a range of psychiatric illnesses, offering a promising avenue to address current treatment gaps and mitiga…
This systematic review provides compelling evidence for the superior efficacy of semaglutide among current pharmacological options for obesity management. The substantial weight loss achieved with semaglutide, a GLP-1…
This comprehensive meta-analysis provides strong evidence supporting retatrutide's exceptional efficacy and acceptable safety profile, positioning it as a highly promising therapeutic option for individuals with obesi…
This research is profoundly significant as it uncovers a direct cardiac effect of retatrutide, distinct from its well-documented metabolic actions. Understanding these direct myocardial influences is paramount for dev…
Free, no account — handy when you're working with Retatrutide.